Indication:Renal anaemia or anaemia associated with chemotherapy
Drug Safety Update
Epoetin beta (NeoRecormon): increased risk of retinopathy in preterm infants cannot be excluded. Further information at:https://www.gov.uk/drug-safety-update/epoetin-beta-neorecormon-increased-risk-of-retinopathy-in-preterm-infants-cannot-be-excluded
1.1 Erythropoiesis stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.
1.2 If different erythropoiesis stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.